Literature DB >> 33333899

Effect of Obstructive Sleep Apnea and CPAP Treatment on Cardiovascular Outcomes in Acute Coronary Syndrome in the RICCADSA Trial.

Yüksel Peker1,2,3,4, Erik Thunström2,5, Helena Glantz6, Christine Eulenburg7.   

Abstract

We aimed to address the impact of OSA and its treatment with continuous positive airway pressure (CPAP) on major adverse cardiovascular and cerebrovascular events (MACCE) in patients with acute coronary syndrome (ACS). In this current analysis of the revascularized ACS subgroup (n = 353) of the Randomized Intervention with CPAP in Coronary Artery Disease and Obstructive Sleep Apnea (RICCADSA) trial (Trial Registry: ClinicalTrials.gov; No: NCT00519597), participants with non-sleepy OSA (apnea-hypopnea-index [AHI] ≥ 15 events/h on a home sleep apnea testing, and Epworth Sleepiness Scale [ESS] score < 10; n = 171) were randomized to CPAP (n = 86) or no-CPAP (n = 85). The sleepy OSA patients (AHI ≥ 15 events/h and ESS ≥ 10) who were offered CPAP, and the ones with no-OSA (AHI < 5 events/h) were included in the observational arm. A post-hoc analysis was done to compare untreated OSA (no-CPAP; n = 78) and nonadherent sleepy/non-sleepy OSA (n = 96) with the reference group without OSA (n = 81). The primary endpoint (the first event of repeat revascularization, myocardial infarction, stroke or cardiovascular mortality) during a median 4.7-year follow-up was evaluated in time-dependent Cox proportional hazards models adjusted for confounding factors. The incidence of MACCE did not differ significantly in intention-to-treat population. On-treatment analysis showed a significant risk reduction in those who used CPAP for ≥4 vs. <4 h/day or did not receive treatment (adjusted hazard ratio [HR] 0.17; 95% confidence interval [CI] 0.03-0.81; p = 0.03). Compared with the reference group, nonadherent/untreated OSA was associated with an increased cardiovascular risk (adjusted HR 1.97, 95% CI 1.03-3.77; p = 0.04). We conclude that OSA is an independent risk factor for adverse cardiovascular outcomes in patients with ACS. CPAP treatment may reduce this risk, if the device is used at least 4 h/day.

Entities:  

Keywords:  acute coronary syndrome; cardiovascular outcomes; continuous positive airway pressure; obstructive sleep apnea

Year:  2020        PMID: 33333899     DOI: 10.3390/jcm9124051

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  6 in total

1.  A meta-analysis to identify factors associated with CPAP machine purchasing in patients with obstructive sleep apnea.

Authors:  Bundit Sawunyavisuth; Chetta Ngamjarus; Kittisak Sawanyawisuth
Journal:  Biomed Rep       Date:  2022-04-01

2.  Are there sex-related differences in therapeutic CPAP levels in adults undergoing in-laboratory titration?

Authors:  Ricardo L M Duarte; Flavio J Magalhães-da-Silveira; David Gozal
Journal:  J Clin Sleep Med       Date:  2021-09-01       Impact factor: 4.324

3.  Impact of obstructive sleep apnea complicated with type 2 diabetes on long-term cardiovascular risks and all-cause mortality in elderly patients.

Authors:  Xiaofeng Su; Jian Hua Li; Yinghui Gao; Kaibing Chen; Yan Gao; Jing Jing Guo; Min Shi; Xiao Zou; Weihao Xu; Li Bo Zhao; Huanhuan Wang; Yabin Wang; Juan Liu; Hu Xu; Xiaoxuan Kong; Junling Lin; Xiaoshun Qian; Jiming Han; Lin Liu
Journal:  BMC Geriatr       Date:  2021-09-25       Impact factor: 3.921

4.  REM-Predominant Obstructive Sleep Apnea in Patients with Coronary Artery Disease.

Authors:  Baran Balcan; Yeliz Celik; Jennifer Newitt; Patrick J Strollo; Yüksel Peker
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

Review 5.  Cardiovascular Disorders Triggered by Obstructive Sleep Apnea-A Focus on Endothelium and Blood Components.

Authors:  Jakub Mochol; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Helena Martynowicz; Adrian Doroszko
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

6.  Physiological Traits and Adherence to Sleep Apnea Therapy in Individuals with Coronary Artery Disease.

Authors:  Andrey V Zinchuk; Jen-Hwa Chu; Jiasheng Liang; Yeliz Celik; Sara Op de Beeck; Nancy S Redeker; Andrew Wellman; H Klar Yaggi; Yüksel Peker; Scott A Sands
Journal:  Am J Respir Crit Care Med       Date:  2021-09-15       Impact factor: 30.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.